Myung In Pharmaceutical LTD. (KRX:317450)
South Korea · Delayed Price · Currency is KRW 56,900
+600 (1.07%)
At close: Apr 8, 2026
KRX:317450 Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 81,435 | 68,671 | 74,512 | 57,434 | 59,750 |
Depreciation & Amortization | 10,940 | 12,463 | 11,440 | 11,336 | 11,619 |
Loss (Gain) From Sale of Assets | -20.99 | 609.54 | 0.32 | -10.7 | -6.39 |
Loss (Gain) From Sale of Investments | - | 8,310 | -826.42 | - | - |
Provision & Write-off of Bad Debts | 525.33 | -306.25 | 60.61 | -207.87 | 165.58 |
Other Operating Activities | 1,016 | -1,522 | 3,787 | 924.41 | 2,025 |
Change in Accounts Receivable | 101.37 | 941.39 | 262.81 | 2,166 | 579.21 |
Change in Inventory | -4,537 | -5,205 | -8,679 | -1,264 | -2,511 |
Change in Accounts Payable | -1,977 | 5,789 | 268.26 | -115.86 | 236.65 |
Change in Other Net Operating Assets | -5,922 | -6,777 | -4,750 | -9,217 | -5,754 |
Operating Cash Flow | 81,561 | 82,972 | 76,075 | 61,045 | 66,105 |
Operating Cash Flow Growth | -1.70% | 9.07% | 24.62% | -7.65% | 20.04% |
Capital Expenditures | -30,039 | -10,189 | -4,647 | -3,402 | -2,697 |
Sale of Property, Plant & Equipment | 23.06 | 180.61 | - | 13.5 | 6 |
Sale (Purchase) of Intangibles | -4,808 | -3.26 | -1.43 | -0.56 | 319.08 |
Investment in Securities | -228,705 | -66,883 | -28,866 | -68,030 | -65,086 |
Other Investing Activities | - | - | -6,295 | -17,527 | -5,915 |
Investing Cash Flow | -263,529 | -76,895 | -39,810 | -88,946 | -73,374 |
Long-Term Debt Issued | - | - | 3,840 | 5,480 | 1,052 |
Total Debt Issued | - | - | 3,840 | 5,480 | 1,052 |
Long-Term Debt Repaid | -1,469 | -2,075 | -1,459 | -1,492 | -1,422 |
Total Debt Repaid | -1,469 | -2,075 | -1,459 | -1,492 | -1,422 |
Net Debt Issued (Repaid) | -1,469 | -2,075 | 2,381 | 3,989 | -369.77 |
Issuance of Common Stock | 193,782 | - | - | - | - |
Dividends Paid | -11,200 | -5,600 | -22,400 | -11,200 | -14,000 |
Other Financing Activities | -0 | - | - | - | - |
Financing Cash Flow | 181,113 | -7,675 | -20,019 | -7,211 | -14,370 |
Foreign Exchange Rate Adjustments | -250.01 | 45.27 | -48.1 | 396.58 | 4,102 |
Net Cash Flow | -1,105 | -1,552 | 16,198 | -34,716 | -17,537 |
Free Cash Flow | 51,522 | 72,783 | 71,428 | 57,643 | 63,407 |
Free Cash Flow Growth | -29.21% | 1.90% | 23.91% | -9.09% | 39.39% |
Free Cash Flow Margin | 17.94% | 27.01% | 29.47% | 25.52% | 30.30% |
Free Cash Flow Per Share | 4250.33 | 6498.19 | 6377.48 | 5146.68 | 5661.37 |
Cash Interest Paid | - | - | - | - | 137.2 |
Cash Income Tax Paid | 22,454 | 22,782 | 16,300 | 26,812 | 15,695 |
Levered Free Cash Flow | 27,589 | 60,205 | 51,018 | 48,309 | 56,598 |
Unlevered Free Cash Flow | 27,736 | 60,406 | 51,227 | 48,376 | 56,681 |
Change in Working Capital | -12,335 | -5,252 | -12,898 | -8,430 | -7,449 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.